Key Moments
This Startup Wants To Catch Cancer Before It Spreads
Y CombinatorKey Moments
Startup BillionToOne converts a needle-in-a-haystack prenatal DNA test into a potential early cancer detection tool, but the $4B valuation company faces the challenge of convincing doctors and patients for widespread adoption.
Key Insights
BillionToOne's prenatal test, which detects rare fetal DNA fragments in maternal blood, is used for 1 in 11 babies born in the U.S. this year.
The company has achieved close to 20% market share in its prenatal testing sector, processing over 600,000 tests annually.
Their core innovation involves adding synthetic DNA to samples before amplification to quantify and subtract amplification-induced errors, improving signal detection.
BillionToOne launched commercially with a cancer test in 2023, as step two in their three-step plan, following their prenatal testing success.
An early cancer patient, ineligible for immunotherapy based on tumor testing, responded remarkably well after BillionToOne's test identified a specific genetic marker, leading to increased physician referrals.
The company aims for step three: detecting microscopic residual tumor DNA after curative surgery in stage one and two cancer patients, with an eventual goal of universal early-stage cancer screening.
Solving the 'needle in a haystack' DNA detection problem
BillionToOne tackles the immense challenge of detecting extremely rare DNA fragments in a sea of billions of other DNA molecules. This 'needle in a haystack' problem is central to their work, whether identifying a single base pair difference for genetic disorders like sickle cell disease or detecting minuscule cancer DNA in blood. Their company name, BillionToOne, reflects this inherent difficulty. The core innovation lies in a process that adds synthetic DNA to patient samples *before* PCR amplification. This synthetic DNA acts as an internal calibrator, allowing the system to accurately measure how much amplification has occurred and what errors have been introduced across different genomic locations. By knowing these amplification biases, the system can effectively subtract the 'noise' from the sequencing data. This clever approach transforms a complex biological detection problem into a more manageable mathematical one, enabling the detection of signals previously lost in amplification distortion.
Revolutionizing prenatal testing with high accuracy
BillionToOne's initial success came from applying their technology to non-invasive prenatal testing (NIPT). Prior to their innovation, detecting fetal genetic abnormalities typically required invasive procedures like amniocentesis, which carry risks and are thus reserved for high-risk pregnancies. BillionToOne's method, by contrast, analyzes fragments of cell-free fetal DNA circulating in the mother's bloodstream. This approach has rapidly gained traction, with 1 in 11 babies born in the U.S. this year being screened using their technology. The company reports processing over 600,000 tests annually and holds an impressive market share close to 20% in this sector, demonstrating significant commercial adoption and trust. They have scaled their operations to a state-of-the-art lab capable of processing millions of samples, aiming to test approximately one in three babies born.
From PhD idea to commercial reality in record time
The founders, Ozan and David, started with a radical concept and minimal resources – half a lab bench and $300,000 – setting up their initial operations in a shared facility. They faced significant hurdles, including difficulties in procuring basic lab supplies due to lack of established business infrastructure. Fundraising was a strenuous six-month process for their initial $300,000. Despite these challenges, they developed a working test and proved its accuracy within six months of applying to Y Combinator. The initial commercial launch was slow, with only one physician using the test two months later. This prompted an emergency meeting and a bold sales strategy shift: rapidly hiring and training five new sales representatives to actively engage physicians and patients, recognizing that patient demand could drive physician adoption.
Leveraging technology for operational efficiency
As BillionToOne scaled, they encountered bottlenecks even in routine laboratory processes. For instance, logging and tracking over thousands of samples daily required significant manual effort, with each file taking a human operator about 60 seconds. To overcome this, they integrated AI and computer vision into their workflow. Their 'Accessioning in 60 Seconds' project dramatically accelerated sample processing. Further automation is achieved through liquid handling robots equipped with optics to precisely extract the cell-free DNA-rich plasma. The company also manufactures its proprietary quantitative counting templates (QCTs) in-house, which are critical for measuring and correcting biases in the amplification process. These technological advancements are key to handling high volumes efficiently and preserving sample identity throughout the multi-day processing pipeline.
Transitioning to cancer diagnostics: The 'holy grail'
BillionToOne's long-term vision extends beyond prenatal testing to early-stage cancer detection, a goal described as the 'holy grail' of diagnostics. The fundamental science is the same: cancer cells, like fetal cells, shed DNA fragments into the bloodstream (cell-free tumor DNA). The company launched an early version of its cancer test commercially in 2023, marking step two in their strategic roadmap, which began with prenatal genetics and will progress to late-stage, then early-stage cancers. They believe that detecting tumor DNA is technically similar to detecting fetal DNA, and leveraging their existing NIPT success provided the necessary resources and validation to tackle the more complex oncology market. This phased approach allowed them to build commercial traction and refine their technology before aiming for the most challenging diagnostic frontier.
A life-saving intervention for a late-stage cancer patient
A compelling patient story highlights the impact of BillionToOne's cancer technology. A patient in their 40s with metastatic colorectal cancer had exhausted treatment options and was nearing hospice care. Standard tumor testing did not indicate eligibility for immunotherapy. However, BillionToOne's Northstar Select test, analyzing cell-free tumor DNA in the patient's bloodstream, identified microsatellite instability. This finding suggested the patient might respond to immunotherapy despite the tumor biopsy revealing no such indication, likely because the biopsy site didn't capture the specific mutation present in other metastatic sites. The patient underwent immunotherapy and experienced a remarkable recovery, with the cancer reportedly 'melting away.' This success has led the treating physician to refer nearly all his cancer patients for BillionToOne's blood tests.
The path to early cancer detection and universal screening
Step three of BillionToOne's plan involves detecting minimal residual disease (MRD) – microscopic amounts of remnant tumor DNA that might remain after curative surgery for stage one and two cancers. Current scans often cannot detect these microscopic residues, which are present in about 20% of such patients and can lead to recurrence. BillionToOne aims to identify this remnant DNA, offering critical information for further treatment decisions. The ultimate goal, step four, is to achieve universal cancer screening for the general population. If they can reliably detect cancer at a microscopic DNA level in healthy individuals, tumors could be identified and treated before they spread, potentially revolutionizing cancer care and saving millions of lives. This ambitious objective requires overcoming significant technical and regulatory hurdles but represents the pinnacle of their technological development.
Building a team for ambitious challenges
BillionToOne actively seeks 'interdisciplinary people' rather than just building interdisciplinary teams, believing this internal integration accelerates innovation. They structure their research teams to be small and agile, typically comprising a principal investigator and two to three associates who report directly to the founders. This model allows for end-to-end product ownership and rapid iteration, minimizing bureaucratic delays. Each small team functions like a 'startup within the company,' owning a product and driving its continuous improvement. The company's public offering and growth attract employees who are motivated by the challenge of transforming healthcare, even if they could easily retire. They embrace the philosophy 'pressure is a privilege,' acknowledging that changing healthcare while growing rapidly and profitably is exceptionally difficult but ultimately deeply rewarding.
Mentioned in This Episode
●Products
●Software & Apps
●Companies
●Organizations
●Drugs & Medications
●Concepts
●People Referenced
Billion to One: Key Takeaways
Practical takeaways from this episode
Do This
Avoid This
Billion to One's Strategic Market Expansion Plan
Data extracted from this episode
| Step | Market Focus | Description |
|---|---|---|
| Step 1 | Prenatal Genetic Testing | Detecting fetal DNA in maternal blood; used as the initial commercial product. |
| Step 2 | Late-Stage Cancer Detection (Liquid Biopsy) | Leveraging the same technology to detect tumor DNA in blood; achieved commercialization in 2023. |
| Step 3 | Early-Stage Cancer Detection (MRD) | Detecting minimal residual disease after treatment for Stage I-II cancers. |
| Step 4 (Eventual Goal) | General Cancer Screening | Screening the general population annually for early-stage cancer detection. |
Common Questions
The main challenge is the 'needle in a haystack' problem: identifying a single, rare base pair difference out of billions of DNA base pairs. Traditional methods amplify the DNA, introducing noise that can obscure the signal.
Topics
Mentioned in this video
A next-generation molecular diagnostics company focused on detecting DNA in blood samples, starting with prenatal genetic testing and expanding into cancer detection.
Mentioned as an analogy for Billion to One's own three-step strategic plan, highlighting a phased approach to market expansion.
Minimal Residual Disease test for stage one cancer patients, an ultra-sensitive test Billion to One is developing.
Polymerase Chain Reaction, a process used in molecular diagnostics to amplify DNA, which Billion to One's technology aims to improve by reducing noise.
An invasive procedure previously used to detect genetic abnormalities, contrasted with Billion to One's non-invasive blood test.
Artificial Intelligence incorporated into Billion to One's processes, particularly for accelerating sample accessioning using computer vision.
Used in conjunction with AI to redesign sample accessioning processes, speeding them up significantly.
More from Y Combinator
View all 579 summaries
32 minThis AI Company Catches Fraud Across the Internet
58 minFrançois Chollet: ARC-AGI-3, Beyond Deep Learning & A New Approach To ML
14 minInside The Startup Reinventing The $6 Trillion Chemical Manufacturing Industry
1 minThis Is The Holy Grail Of AI
Found this useful? Build your knowledge library
Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.
Get Started Free